Celiac Disease Genetic Test (HLA-DQ2/DQ8)

A genetic blood test for the HLA-DQ2 and HLA-DQ8 alleles determining genetic susceptibility to celiac disease — the most common gastrointestinal autoimmune condition in Europe, affecting approximately 1% of the population but with over 80% of cases estimated to remain undiagnosed. Available at 2,052 Kč including specialist interpretation through cz.unilabs.online. Unlike standard serological celiac tests (which only turn positive after gluten exposure has already caused intestinal damage), the genetic test identifies lifelong susceptibility before or without gluten ingestion — and is unaffected by current diet. Results in 10 business days. Rated 4.86/5 across 63 reviews.

Celiac disease is an autoimmune condition triggered by dietary gluten in genetically predisposed individuals. The HLA genetic variants DQ2 and DQ8 on chromosome 6 are necessary for the development of celiac disease: approximately 95% of celiac patients carry HLA-DQ2, and most of the remainder carry HLA-DQ8. People who carry neither variant have a near-zero lifetime risk of developing celiac disease, regardless of gluten exposure. This genetic test is particularly valuable in three scenarios: Gluten-free diet already in progress: Standard serological tests (anti-TTG IgA, anti-gliadin antibodies) turn negative after several months on a strict gluten-free diet. The HLA genetic test is not affected by diet — it reflects inherited genotype. First-degree relatives of confirmed celiac patients: Siblings and parents of celiac patients have a 10–15% lifetime risk. Genetic testing allows the clinician to exclude celiac risk entirely if the relative carries neither DQ2 nor DQ8. Symptomatic patients where serology is equivocal or IgA deficiency complicates interpretation: Total IgA deficiency (present in approximately 1 in 500 people) renders standard IgA-based celiac serology unreliable. The test includes specialist physician interpretation via uLékaře.cz — one of the few Unilabs products where interpretation is bundled into the price, reflecting the complexity of communicating HLA results correctly.